vemurafenib · Hoffmann La Roche · NDA 202429
Zelboraf
Earliest generic entry, as listed
6 Jun 2032
Blocked by patent: US 9447089.
Listed patents · 3 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 9447089 | product | 6 Jun 2032 |
| US 8741920 | substance, product | 27 Jul 2030 |
| US 7863288 | substance, product | 20 Jun 2029 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 202429 · 001 · RLD | tablet, oral | 240MG | 6 Jun 2032 |
Expired or delisted (4)
- US 7504509 · substance, product · 22 Oct 2026
- US 8470818 · use U-1418 · 2 Aug 2026
- US 8470818 · use U-2164 · 2 Aug 2026
- US 8143271 · substance, product · 21 Jun 2026